Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance dasatinib or sorafenib after allogeneic hematopoietic stem cell transplantation for core-binding factor acute myeloid leukemia
ChiCTR1800018392Phase 2Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Sep 2018
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of dasatinib and sorafenib in acute myeloid leukemia (AML) (3 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: overall survival, disease-free survival and 5 more. Started Sep 2018; status: recruiting.
02
Drugs
dasatinibsorafenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR1800018392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018392.